PRASUGREL SWANPOND INVESTMENTS
As listed in the register: PRASUGREL SWANPOND INVESTMENTS 10 MG COMPRIMIDOS RECUBIERTOS CON PELICULA EFG
10 mg · comprimido recubierto con película
- Prescription only
- Blood, clotting and anaemia
- Active substance
- Prasugrel
- Used in
- Blood, clotting and anaemia
- Made by
- Swan Pond Investments Limited
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
Mediclarum has not yet retrieved and stored the official label for this product, so none of its text is shown here. Open the official leaflet
How it works
From the US prescribing label for the same active substance (PRASUGREL). It describes the substance, not this exact product.
Prasugrel is an inhibitor of platelet activation and aggregation through the irreversible binding of its active metabolite to the P2Y 12 class of ADP receptors on platelets.
Prasugrel is a prodrug and is rapidly metabolized to a pharmacologically active metabolite and inactive metabolites.
Approximately 68% of the prasugrel dose is excreted in the urine and 27% in the feces as inactive metabolites.
In a study of healthy subjects given a single 15 mg dose, the AUC of the active metabolite was unaffected by a high fat, high calorie meal, but C max was decreased by 49% and T max was increased from 0.5 to 1.5 hours.
Quoted from the prescribing label, sections “Mechanism of Action” and “Pharmacokinetics”. DailyMed · 2026-04-08
Safety of the active substance
From the US prescribing label for the same active substance (PRASUGREL). It describes the substance, not this exact product.
WARNING: BLEEDING RISK Prasugrel tablets can cause significant, sometimes fatal, bleeding [see Warnings and Precautions ( 5.1, 5.2 ) and Adverse Reactions ( 6.1 )].
- In TRITON-TIMI 38 ( TR ial to Assess I mprovement in T herapeutic Outcomes by O ptimizing Platelet Inhibitio N with prasugrel), patients with a history of TIA or ischemic stroke (>3 months prior to enrollment) had a higher rate of stroke on prasugrel tablets (6.5%; of which 4.2% were thrombotic stroke and 2.3% were intracranial hemorrhage [ICH]) than on clopidogrel (1.2%; all thrombotic).
- In patients without such a history, the incidence of stroke was 0.9% (0.2% ICH) and 1.0% (0.3% ICH) with Prasugrel tablets and clopidogrel, respectively.
- Patients with a history of ischemic stroke within 3 months of screening and patients with a history of hemorrhagic stroke at any time were excluded from TRITON-TIMI 38.
- Patients who experience a stroke or TIA while on Prasugrel tablets generally should have therapy discontinued [see Adverse Reactions ( 6.1 ) and Clinical Studies ( 14 )]. 4.3 Hypersensitivity Prasugrel tablet is contraindicated in patients with hypersensitivity (e.g., anaphylaxis) to prasugrel or any component of the product [see Adverse Reactions ( 6.2 )].
The most common adverse reaction leading to study drug discontinuation for both drugs (2.5% for prasugrel tablets and 1.4% for clopidogrel).
Quoted from the US prescribing label for the same active substance. Your own pack’s leaflet is the authority for your product. DailyMed
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
United States11 matching products
European UnionNo exact match for this strength and form
France2 matching products
Netherlands5 matching products
- Efient 10 mg filmomhulde tabletten 10 mg · filmomhulde tablet
- Prasugrel ratiopharm 10 mg 10 mg · filmomhulde tablet
- Prasugrel Teva 10 mg 10 mg · filmomhulde tablet
- Prasugrel Viatris 10 mg filmomhulde tabletten 10 mg · filmomhulde tablet
- Prasugrel Vivanta 10 mg filmomhulde tabletten 10 mg · filmomhulde tablet
SwitzerlandNo exact match for this strength and form
Details
| Made by | Swan Pond Investments Limited |
|---|---|
| Active substance | Prasugrel |
| Used in | Blood, clotting and anaemia |
| Strength | 10 mg |
| Form | comprimido recubierto con película |
| Classification | B01AC22 · Blood, clotting and anaemia |
| Route | vía oral |
| Marketed | No — authorised but not currently marketed, according to the register |
| Generic | Yes — a generic medicine, according to the register |
| Name in the register | PRASUGREL SWANPOND INVESTMENTS 10 MG COMPRIMIDOS RECUBIERTOS CON PELICULA EFG |
| Nº Registro | 83790 |
Source: CIMA — Centro de Información online de Medicamentos · 2026-09-30 · not reviewed by a clinician
Fuente: Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), CIMA. Reuse terms: Aviso legal AEMPS.
Same active substance
These contain the same substance. That does not mean one can replace another — ask a pharmacist.